{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:41:20Z","timestamp":1760924480695,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biologicals"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.biologicals.2019.07.001","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T19:36:47Z","timestamp":1563478607000},"page":"52-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Prescription-based prevalence of biological therapy in patients with psoriasis, rheumatoid arthritis, and inflammatory bowel diseases"],"prefix":"10.1016","volume":"61","author":[{"given":"Karel","family":"Kostev","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meike","family":"Madelung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biologicals.2019.07.001_bib1","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/j.jaad.2005.10.057","article-title":"Innate and adaptive immunity and the pathophysiology of psoriasis","volume":"54","author":"Gaspari","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.biologicals.2019.07.001_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/MIB.0000000000000955","article-title":"An overview of the innate and adaptive immune system in inflammatory bowel disease","volume":"23","author":"Choy","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.biologicals.2019.07.001_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.immuni.2017.02.006","article-title":"Immunopathogenesis of rheumatoid arthritis","volume":"46","author":"Firestein","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.biologicals.2019.07.001_bib4","doi-asserted-by":"crossref","first-page":"125sr1","DOI":"10.1126\/scitranslmed.3003504","article-title":"Treating human autoimmunity: current practice and future prospects","volume":"4","author":"Rosenblum","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.biologicals.2019.07.001_bib5","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/jhg.2015.94","article-title":"Genetics of autoimmune diseases: insights from population genetics","volume":"60","author":"Ramos","year":"2015","journal-title":"J Hum Genet"},{"key":"10.1016\/j.biologicals.2019.07.001_bib6","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/jcp.2005.032300","article-title":"Biologic therapies: what and when?","volume":"60","author":"Johnston","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.biologicals.2019.07.001_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: an update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.biologicals.2019.07.001_bib8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1741-7015-12-43","article-title":"What is the future of targeted therapy in rheumatology: biologics or small molecules?","volume":"12","author":"M\u00f3csai","year":"2014","journal-title":"BMC Med"},{"key":"10.1016\/j.biologicals.2019.07.001_bib9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1759720X14551568","article-title":"Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know","volume":"6","author":"Krause","year":"2014","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.biologicals.2019.07.001_bib10","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s00296-011-2033-5","article-title":"Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study","volume":"32","author":"Kleinert","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.biologicals.2019.07.001_bib11","first-page":"386148","article-title":"Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine","author":"Da\u00efen","year":"2014","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.biologicals.2019.07.001_bib12","unstructured":"Gossen N, Waehlert L, May U, Kostev K. Die rolle des privaten versicherungsstatus bei der initiierung der therapie mit biologika in rheumatologischen praxen in Deutschland. http:\/\/www.egms.de\/en\/meetings\/dkvf2015\/15dkvf203.shtml."}],"container-title":["Biologicals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105619300764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1045105619300764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T01:13:39Z","timestamp":1760922819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1045105619300764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":12,"alternative-id":["S1045105619300764"],"URL":"https:\/\/doi.org\/10.1016\/j.biologicals.2019.07.001","relation":{},"ISSN":["1045-1056"],"issn-type":[{"type":"print","value":"1045-1056"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescription-based prevalence of biological therapy in patients with psoriasis, rheumatoid arthritis, and inflammatory bowel diseases","name":"articletitle","label":"Article Title"},{"value":"Biologicals","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biologicals.2019.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}